Drug Type Bispecific antibody |
Synonyms |
Target- |
Action stimulants |
Mechanism ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), T lymphocytes stimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Bladder Cancer | Preclinical | Switzerland | 01 Mar 2022 | |
| Esophageal Carcinoma | Preclinical | Switzerland | 01 Mar 2022 | |
| Lung Cancer | Preclinical | Switzerland | 01 Mar 2022 |






